Physician

Tingting Tan, M.D. PH.D.

According to 2025 Medicare claims, Tingting Tan, M.D. PH.D. (NPI: 1669627238) practices hematology/oncology in the Anaheim-Santa Ana-Irvine, CA market, with the plurality of this provider's patient population coming from Orange, CA. This provider's primary affiliated billing organization is CITY OF HOPE MEDICAL FOUNDATION (NPI: 1871886366; TIN: 274803222) and primary practice location at 92660-7725. Tan is affiliated with the Optum California ACO (ACO ID: A5045), participating under the MSSP model.

Tan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 514 traditional Medicare patients, billed 144,069 HCPCS/CPT codes, and received $2,665,041 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,017 prescription claims across 180 beneficiaries totaling $4,606,125 in drug costs, led by Tagrisso (Osimertinib Mesylate). DME data shows 27 claims. Open Payments data shows 2 records totaling $29. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $185,486 to $2,665,041. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $941,904 and ending at $4,606,125. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	178	26,341	$185,486
2016	342	51,960	$378,539
2017	336	30,332	$359,798
2018	307	40,298	$440,169
2019	319	23,561	$349,648
2020	147	29,902	$657,162
2021	258	81,538	$1,316,470
2022	355	120,673	$2,082,442
2023	424	85,217	$1,632,164
2024	514	144,069	$2,665,041

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	111	635	$941,904
2016	114	755	$1,075,027
2017	130	923	$1,158,165
2018	116	847	$1,642,824
2019	98	688	$1,499,800
2020	73	356	$364,648
2021	59	375	$603,804
2022	69	465	$903,572
2023	127	644	$2,612,851
2024	180	1,017	$4,606,125

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	58	$3,634
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	102	$60,216
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	27	$974

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	136	299	$142
96413	Administration of chemotherapy into vein, 1 hour or less	77	269	$118
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	183	308	$95
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	78	129	$57
96372	Injection of drug or substance under skin or into muscle	95	212	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	66	1,980	$1,064,942
Kisqali	Ribociclib Succinate	39	1,092	$645,536
Ibrance	Palbociclib	34	882	$476,723
Verzenio	Abemaciclib	19	534	$274,714
Tasigna	Nilotinib Hcl	12	336	$226,068

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	16	$767
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$207

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$29	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Tingting Tan, M.D. PH.D.?

Tedicare shows public-source Medicare data for Tingting Tan, M.D. PH.D. (NPI 1669627238), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Tingting Tan, M.D. PH.D. have ACO affiliation data?

Tingting Tan, M.D. PH.D. is shown with ACO affiliation data for Optum California ACO (MSSP, ACO ID A5045).

What billing organization is linked to Tingting Tan, M.D. PH.D.?

Tingting Tan, M.D. PH.D. is linked to CITY OF HOPE MEDICAL FOUNDATION (billing NPI 1871886366) in the available physician profile data.

Does Tingting Tan, M.D. PH.D. have Open Payments data?

Tingting Tan, M.D. PH.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.